Eli Lilly, type 2 diabetes
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
A turbulent series of events surrounding the supply of Eli Lilly ... obesity, after almost two years. By law, that should have prohibited compound pharmacies from making copies of the drug ...
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...
Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...
So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback